Background Forkhead Box P1 (FOXP1) has been described as both a tumour suppressor candidate and a potential oncogene. The aim of this study is to identify new prognostic biomarkers and therapeutic target structures for the diagnosis and treatment of hepatocellular carcinoma (HCC).
Methods The expression of FOXP1 mRNA in HCC was characterised using real-time PCR and 20 pairs of fresh frozen HCC tissues and corresponding non-cancerous tissues. FOXP1 protein expression in HCC was confirmed using immunohistochemistry on a tissue microarray chip. Finally, FOXP1 expression was correlated with conventional clinicopathological features of HCC and patient outcome.
Results The expression of FOXP1 mRNA and protein in HCC cells was much higher than in normal hepatic cells (Z=2.315, p=0.021 and χ2=28.071, 95% CI 0.233 to 0.480, p<0.001, individually). The comparison of clinicopathological characteristics and immunohistochemistry by χ2 test analysis showed that the high expression of FOXP1 in HCC was related to large tumour diameter (χ2=6.210, p=0.013), high serum α-fetoprotein levels (χ2=6.920, p=0.031) and later stage grouping with tumour node metastasis classification (χ2=6.714, p=0.035). Kaplan–Meier survival and Cox regression analysis showed that high FOXP1 expression (HR=2.182, 95% CI 1.146 to 4.154, p=0.018) and regional lymph node metastasis (HR=2.326, 95% CI 1.037 to 5.217, p=0.041) were independent prognosis factors.
Conclusions From this investigation the authors elucidated for the first time that the correlation of high FOXP1 expression correlates with an aggressive malignant phenotype and may constitute a novel prognostic factor for HCC. These results also support a role for FOXP1 as an oncogene in HCC.
- prognostic factor
- liver cancer
- cancer research
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
YZ and SZ contributed equally to this study.
Funding This study was supported by grants from the Social Development and Applied Research Projects (K2010012) of Nantong, Jiangsu Province, China, and the International Cooperation and Exchanges (2011) from the Department of Health of Jiangsu Province, China.
Competing interests None.
Ethics approval This study was conducted with the approval of the Human Research Ethics Committee of the Affiliated Tumor Hospital of Nantong University.
Provenance and peer review Not commissioned; externally peer reviewed.